Solid Biosciences (SLDB) Stock Statistics & Valuation Metrics

Solid Biosciences has a market cap or net worth of $210.01M. The enterprise value is $46.08M.

Solid Biosciences has 77.49M shares outstanding. The number of shares has decreased by -2.65% in one year.

Solid Biosciences’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -80.37%.

The current PE Ratio of Solid Biosciences is -1.31. Solid Biosciences’s PEG ratio is 0.04.

In the last 12 months, Solid Biosciences had revenue of $0.00 and earned -$124.70M in profits. Earnings per share was -$3.08.

In the last 12 months, operating cash flow was -$100.01M and capital expenditures -$654.00K, giving a free cash flow of -$100.67M billion.

Solid Biosciences pays an annual dividend of , resulting in a dividend yield of

Solid Biosciences upcoming earnings date is May 8, 2025, TBA.

Solid Biosciences as a current ratio of 5.20, with Debt / Equity ratio of 0.18

In the past 12 months, Solid Biosciences has paid -$951.28K in taxes.

Solid Biosciences EV to EBITDA ratio is -0.83, with an EV/FCF ratio of -1.06.

Solid Biosciences has $148.92M in cash and marketable securities with $24.18M in debt, giving a net cash position of -$124.74M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Solid Biosciences is $17.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy